BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Aug. 2, 2007
View Archived Issues
Hana Licenses Zensana To Par, Focuses On Oncology Pipeline
Hana Biosciences Inc., which earlier this year withdrew a new drug application filing for the antiemetic agent Zensana, licensed the product to Par Pharmaceutical Cos. Inc. (BioWorld Today)
Read More
Advisory Panel: Thumbs Up To Tysabri For Limited Use In CD
Read More
Better Magnetic Nanoparticle May Enable Virus-Free Gene Therapy
Read More
Diagnostic Lab Firm Genoptix Files for $86.25 Million IPO
Read More
Clinic Roundup
Read More
Other News To Note
Read More
Appointments And Advancements
Read More